| Literature DB >> 35539093 |
Zhen-Zhu Zhao1,2, Xu-Bo Liang1, Wei-Sheng Feng1,2, Ya Wu1,2, Yan-Le Zhi1,2, Gui-Min Xue1,2, He-Ping Chen3, Ji-Kai Liu3.
Abstract
Extensive studies have revealed that triterpenoids, meroterpenoids, and polysaccharides are the main constituents of the well-known traditional Chinese medicinal mushroom Ganoderma. In this study, we report seven previously undescribed sesquiterpenoids, including six gymnomitranes (1-6) and a novel type of sesquiterpenoid (8), together with a polyketide (7) and a known steroid (9) from the fruiting bodies of Ganoderma lingzhi, a fungus used as traditional medicine and food supplement in East Asia for ages. The structures of 1-8 were deduced by analysis of spectroscopic data, X-ray single crystal diffractions and TDDFT/ECD calculations. Compound 8 possessed an unusual 14(7→6)-cuparane scaffold. Compound 9 exhibited weak cytotoxicity against the five human cancer cell lines HL-60, MCF-7, SW480, A549, and SMMC-7721 with IC50 values of 18.0-32.3 μM. A simple structure-activity-relationship (SAR) investigation by acetylating the 5-OH of 9 (9a) suggested that the 5-OH is essential for its cytotoxicity. Additionally, the biosynthetic pathways for compounds 2 and 8 are discussed. This journal is © The Royal Society of Chemistry.Entities:
Year: 2019 PMID: 35539093 PMCID: PMC9075120 DOI: 10.1039/c9ra08566a
Source DB: PubMed Journal: RSC Adv ISSN: 2046-2069 Impact factor: 3.361
Fig. 1Structures of compounds 1–9, and 9a.
1H NMR data of compounds 1–8 (600 MHz)
| No. | 1 | 2 | 3 | 4 | 5 | 6 |
|---|---|---|---|---|---|---|
| 1 | 2.05, dd (11.8, 3.5), 1.37, d (11.8) | 1.77, dd (10.0, 2.5), 1.80, dd (10.0, 2.5) | 2.01, dd (11.5, 4.5), 1.87, d (11.5) | 2.79, dd (11.0, 5.0), 1.42, d (11.0) | 1.67, dd (11.8, 4.5), 1.60, d (11.8) | 1.59, ddd (12.0, 5.0, 2.8), 2.11, d (12.0) |
| 2 | 2.59, d (3.5) | 1.61, t (2.5) | 2.11, d (4.5) | 2.61, d (5.0) | 2.51, d (4.5) | 1.85, d (5.0) |
| 4 | 6.73, t-like (2.5) | 1.86, overlapped, 1.48, ddd (16.8, 7.6, 5.2) | 6.04, br. s | 6.80, dd (4.0, 3.0) | 6.88, d (4.0) | 3.31, dd (11.2, 6.3) |
| 5 | 2.55, dd (22.0, 2.5), 2.24, dd (22.0, 2.5) | 1.84, overlapped, 1.32, ddd (16.8, 13.3, 8.0) | 2.49, dd (21.0, 4.0), 2.16, dd (21.0, 3.0) | 3.95, d (4.0) | 1.82, dd (14.0, 6.3), 1.46, dd (14.0, 11.2) | |
| 8 | 1.50, m, 1.23, m | 5.65, d (5.8) | 1.46, m, 1.17, overlapped | 2.22, ddd (14.0, 9.5, 8.0), 1.64, ddd (14.0, 6.0, 4.0) | 3.74, overlapped | 2.61, d (19.7), 1.89, d (19.7) |
| 9 | 1.76, m, 1.61, m | 5.60, dd (5.8, 2.1) | 1.53, m, 1.43, m | 1.60, m, 1.54, m | 1.74, m | |
| 10 | 3.67, t-like (5.0) | 4.11, d (2.1) | 1.59, overlapped, 1.36, m | 1.69, ddd (14.0, 7.0, 4.0), 1.25, m | 1.27, m, 1.14, overlapped | 3.00, d (19.8), 2.13, d (19.8) |
| 12 | 1.06. s | 1.11, s | 1.17, s | 1.21, s | 1.12, s | 1.22, s |
| 13 | 0.94, s | 0.97, s | 0.98, s | 1.05, s | 1.01, s | |
| 14 | 0.99, s | 0.94, s | 1.07, s | 1.13, s | 0.93, s | 0.90, s |
| 15 | 9.45, s | 3.43, d (10.0), 3.27, d (10.0) | 4.35, br. dd (17.0, 6.0), 4.25, br. dd (17.0, 6.0) | 1.38, s | ||
| MeO- | 3.74, s |
Measured in CD3OD.
Measured in CDCl3.
13C NMR Data of Compounds 1–8 (150 MHz)
| No. | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 |
|---|---|---|---|---|---|---|---|---|
| 1 | 42.0, CH2 | 38.0, CH2 | 47.1, CH2 | 43.7, CH2 | 38.3, CH2 | 37.4, CH2 | 178.5, C | 50.4, CH2 |
| 2 | 42.1, CH | 53.9, CH | 49.0, CH | 47.1, CH | 46.5, CH | 57.9, CH | 125.1, C | 197.8, C |
| 3 | 147.6, C | 69.7, C | 169.5, C | 137.7, C | 140.0, C | 72.6, C | 152.7, CH | 135.4, C |
| 4 | 151.0, CH | 31.5, CH2 | 122.3, CH | 140.3, CH | 139.0, CH | 69.5, CH | 124.2, C | 142.3, CH |
| 5 | 41.9, CH2 | 32.7, CH2 | 205.5, C | 42.2, CH2 | 71.6, CH | 44.6, CH2 | 166.3, C | 38.4, CH2 |
| 6 | 44.5, C | 43.6, C | 60.4, C | 47.0, C | 47.6, C | 45.4, C | 28.0, CH2 | 43.2, C |
| 7 | 55.6, C | 64.5, C | 55.3, C | 71.6, C | 57.0, C | 50.1, C | 22.2, CH2 | 190.4, C |
| 8 | 32.7, CH2 | 142.3, CH | 37.9, CH2 | 31.6, CH2 | 76.2, CH | 48.4, CH2 | 40.2, CH | 130.0, CH |
| 9 | 35.2, CH2 | 130.2, CH | 26.9, CH2 | 28.3, CH2 | 35.4, CH2 | 219.6, C | 62.6, CH | 207.1, C |
| 10 | 77.6, CH | 88.8, CH | 39.2, CH2 | 40.1, CH2 | 33.6, CH2 | 50.5, CH2 | 23.7, CH2 | 55.2, CH2 |
| 11 | 61.3, C | 52.4, C | 56.9, C | 61.6, C | 59.3, C | 49.7, C | 11.9, CH3 | 45.1, C |
| 12 | 19.6, CH3 | 27.4, CH3 | 28.1, CH3 | 30.6, CH3 | 27.7, CH3 | 30.9, CH3 | 66.2, CH2 | 29.2, CH3 |
| 13 | 24.4, CH3 | 24.7, CH3 | 22.8, CH3 | 178.7, C | 20.0, CH3 | 24.5, CH3 | 29.4, CH3 | |
| 14 | 24.2, CH3 | 20.0, CH3 | 17.6, CH3 | 24.7, CH3 | 15.9, CH3 | 23.3, CH3 | 27.6, CH3 | |
| 15 | 193.0, CH | 74.2, CH2 | 65.6, CH2 | 170.7, C | 169.1, C | 27.7, CH3 | 15.4, CH3 | |
| MeO- | 52.5, CH3 | 59.1, CH3 |
Measured in CD3OD.
Measured in CDCl3.
Fig. 2Selected HMBC and 1H–1H COSY correlations of 1–8.
Fig. 3Selected ROESY correlations of 1–8.
Fig. 4ORTEP drawing of compound 1.
Fig. 5ORTEP drawing of compound 5.
1H NMR Data of Compounds 7 and 8 (600 MHz, CD3OD)
| No. | 7 | 8 |
|---|---|---|
| 1 | 2.87, d (15.8), 2.59, d (15.8) | |
| 3 | 7.77, s | |
| 4 | 6.64, br. dd (6.0, 3.0) | |
| 5 | 2.83, dd (17.6, 2.4), 2.50, dd (17.6, 2.4) | |
| 6 | 2.59, overlapped | |
| 7 | 1.79, m, 1.71, overlapped | |
| 8 | 1.44, m | 5.93, s |
| 9 | 4.87, d (3.2) | |
| 10 | 1.70, overlapped, 1.42, overlapped | 2.36, s (2H) |
| 11 | 1.01, t (7.0) | |
| 12 | 4.32, d (12.4), 4.29, d (12.4) | 1.38 s |
| 13 | 1.40, s | |
| 14 | 1.37, s | |
| 15 | 1.78, s | |
| MeO- | 3.44, s |
Fig. 6Comparison of the experimental CD and calculated ECD spectra of compound 8.
Cytotoxicity of 9 toward five human cancer cell lines
| Sample | HL-60 | A-549 | SMMC-7721 | MCF-7 | SW480 |
|---|---|---|---|---|---|
| IC50 (μM) | |||||
| 9 | 18.8 | 32.3 | 25.1 | 18.1 | 22.3 |
| DDP | 4.7 | 27.6 | 16.0 | 34.8 | 16.1 |
| Taxol | <0.008 | <0.008 | <0.008 | <0.008 | <0.008 |
Scheme 1Proposed biosynthetic pathway of 2 and 8.